4.6 Review

Comorbid Bipolar and Alcohol Use Disorder-A Therapeutic Challenge

期刊

FRONTIERS IN PSYCHIATRY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fpsyt.2021.660432

关键词

alcohol use disorder; atypical antipsychotics; bipolar disorder; depression; lithium; psychotherapy; valproate

向作者/读者索取更多资源

Comorbidity rates in Bipolar disorder are highest among major mental disorders, especially comorbid substance use. Alcohol is the most frequently abused substance, with significant influence on the severity and prognosis of Bipolar disorder. Further research is needed to develop evidence-based approaches for integrated treatment of this common comorbidity.
Comorbidity rates in Bipolar disorder rank highest among major mental disorders, especially comorbid substance use. Besides cannabis, alcohol is the most frequent substance of abuse as it is societally accepted and can be purchased and consumed legally. Estimates for lifetime comorbidity of bipolar disorder and alcohol use disorder are substantial and in the range of 40-70%, both for Bipolar I and II disorder, and with male preponderance. Alcohol use disorder and bipolarity significantly influence each other's severity and prognosis with a more complicated course of both disorders. Modern treatment concepts acknowledge the interplay between these disorders using an integrated therapy approach where both disorders are tackled in the same setting by a multi-professional team. Motivational interviewing, cognitive behavioral and socio- therapies incorporating the family and social environment are cornerstones in psychotherapy whereas the accompanying pharmacological treatment aims to reduce craving and to optimize mood stability. Adding valproate to lithium may reduce alcohol consumption whereas studies with antipsychotics or naltrexone and acamprosate did not affect mood fluctuations or drinking patterns. In summary, there is a continuous need for more research in order to develop evidence-based approaches for integrated treatment of this frequent comorbidity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Clinical Neurology

Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms

Norma Verdolini, Diego Hidalgo-Mazzei, Laura Del Matto, Michele Muscas, Isabella Pacchiarotti, Andrea Murru, Ludovic Samalin, Alberto Aedo, Mauricio Tohen, Heinz Grunze, Allan H. Young, Andre F. Carvalho, Eduard Vieta

Summary: This systematic review examined international guidelines' recommendations on the long-term treatment of bipolar disorder type I, finding that lithium is the 'gold standard' while quetiapine and aripiprazole are also first-line options. Long-term treatment should initially involve monotherapy, with clinicians regularly monitoring efficacy and side effects.

BIPOLAR DISORDERS (2021)

Review Psychiatry

How Does Adding the DSM-5 Criterion Increased Energy/Activity for Mania Change the Bipolar Landscape?

Anna Grunze, Christoph Born, Mette U. Fredskild, Heinz Grunze

Summary: The DSM-5 redefined the criteria for diagnosing hypomanic/manic episodes, adding increased energy/activity to the previous mood change criterion. Research indicates that this change may lead to a decrease of at least one third in the prevalence of manic/hypomanic episodes, but its impact on clinical practice and research requires further evaluation.

FRONTIERS IN PSYCHIATRY (2021)

Letter Clinical Neurology

Phenotyping of the thoracic-onset variant of amyotrophic lateral sclerosis

Katharina Kandler, Simon Witzel, Konstantin Eder, Dietrich Rothenbacher, Gabriele Nagel, Raphael S. Peter, Joachim Schuster, Johannes Dorst, Angela Rosenbohm, Albert C. Ludolph

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Article Clinical Neurology

Life Course of Physical Activity and Risk and Prognosis of Amyotrophic Lateral Sclerosis in a German ALS Registry

Angela Rosenbohm, Raphael Peter, Johannes Dorst, Jan Kassubek, Dietrich Rothenbacher, Gabriele Nagel, Albert C. Ludolph

Summary: This study found that ALS patients had reduced total PA levels compared to controls at interview and up to 5 years before interview. Total PA was not linked to ALS risk 5 to 55 years before interview, while heavy occupational work intensity was associated with increased risk. Total PA levels were non-linearly associated with survival in ALS cases, with moderate PA showing the best median survival time.

NEUROLOGY (2021)

Review Psychiatry

Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System

Heinz Grunze, Reka Csehi, Christoph Born, Agota Barabassy

Summary: The dopaminergic system plays a crucial role in SUD, BD, and refractory depression, with common genetic markers and underlying cellular processes linking these disorders with a high rate of comorbidity. Dopamine D-3 receptors are central in SUD and BD, suggesting that D-2/D-3 partial agonists/antagonists could be a potential target for both disorders in future therapeutic approaches.

FRONTIERS IN PSYCHIATRY (2021)

Article Psychiatry

Mania and bipolar depression: complementing not opposing poles-a post-hoc analysis of mixed features in manic and hypomanic episodes

Christoph Born, Heinz Grunze, Robert M. Post, Lori L. Altshuler, Ralph Kupka, Susan L. McElroy, Mark A. Frye, Trisha Suppes, Paul E. Keck, Willem A. Nolen, Lars Schaerer

Summary: This study analyzed the presence of depressive symptoms in bipolar disorder patients and found that (hypo)manic states are associated with a higher burden of depression compared to non-(hypo)manic states. Female patients were more likely to exhibit depressive symptoms, and mania and depression were shown to complement each other rather than being opposing poles.

INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS (2021)

Article Clinical Neurology

Are personality disorders in bipolar patients more frequent in the US than Europe?

Robert M. Post, Gabriele S. Leverich, Susan L. McElroy, Ralph Kupka, Trisha Suppes, Lori L. Altshuler, Willem A. Nolen, Mark A. Frye, Paul E. Keck, Heinz Grunze, Michael Rowe

Summary: Compared to Europe, bipolar patients in the US exhibit a higher prevalence of multiple personality disorders, indicating potential differences in the course of illness that require further investigation.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Review Pharmacology & Pharmacy

The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder

Heinz Grunze, Michael Soyka

Summary: This paper explores the available pharmacotherapies for AUD, BD, and their potential utility in comorbid BD and AUD. It also touches on the epidemiology, diagnosis, and common neurobiological traits of comorbid BD and AUD to some extent.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Article Clinical Neurology

Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs

Miriam von Mucke Similon, Cecilia Paasche, Fas Krol, Bernard Lerer, Guy M. Goodwin, Michael Berk, Andreas Meyer-Lindenberg, Terence A. Ketter, Lakshmi N. Yatham, Joseph F. Goldberg, Gin S. Malhi, Rif El-Mallakh, Rasmus W. Licht, Allan H. Young, Flavio Kapczinski, Marnina Swartz, Michal Hagin, Carla Torrent, Alessandro Serretti, Aysegul Yildiz, Anabel Martinez-Aran, Sergio Strejilevich, Janusz Rybakowski, Gabriele Sani, Heinz Grunze, Gustavo Vazquez, Ana Gonzales Pinto, Jean Michel Azorin, Willem Nolen, Othman Sentissi, Carlos Lopez-Jaramillo, Benicio N. Frey, Andrew Nierenberg, Gordon Parker, David J. Bond, Adam Cohen, Alfonso Tortorella, Giulio Perugi, Eduard Vieta, Dina Popovic

Summary: This study provides consensus recommendations for the selection of clinical trial design in psychiatry by surveying clinical and academic experts. The expert panel achieved consensus on 7 out of 21 recommendations regarding the use of randomized clinical trials, strongly supporting their use.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Article Psychiatry

The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management

Roger S. McIntyre, Martin Aida, Ross J. Baldessarini, Michael Bauer, Michael Berk, Christoph U. Correll, Andrea Fagiolini, Kostas Fountoulakis, Mark A. Frye, Heinz Grunze, Lars Kessing, David J. M. Iklowitz, Gordon Parker, Robert M. Post, Alan C. Swann, Trisha Suppes, Eduard Vieta, Allan Young, Mario Maj

Summary: This paper aims to synthesize the clinical characteristics of patients with bipolar disorder to improve their health outcomes and treatment choices. Existing data indicate that certain features of bipolar disorder are associated with illness trajectory, treatment response, and suicide risk. Early environmental exposure is also related to the complexity of the illness.

WORLD PSYCHIATRY (2022)

Review Psychiatry

The detrimental effects of smoking on the course and outcome in adults with bipolar disorder-A narrative review

Anna Grunze, Sergey Mosolov, Heinz Grunze, Christoph Born

Summary: This narrative review examines the epidemiology, consequences, and treatment options of tobacco use disorder (TUD) and nicotine dependence (ND) in individuals with bipolar disorder (BD). The study found that smoking rates are 2-3 times higher in individuals with BD compared to community samples. Smoking has a detrimental impact on both mental and physical health as well as mortality in individuals with BD. Treatment options include pharmacological interventions and psychosocial interventions.

FRONTIERS IN PSYCHIATRY (2023)

Editorial Material Clinical Neurology

Measuring serum concentrations of psychotropics- Valuable tool for decision making or waste of money?

Heinz Grunze

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder

Heinz Grunze

Summary: The comorbidity of substance use disorder with schizophrenia significantly increases morbidity and mortality compared to schizophrenia alone. Dopaminergic dysregulation appears to be a common pathophysiological basis of this comorbidity. Cariprazine, a partial agonist of D3 and D2 dopamine receptors, shows promising results in early clinical observations for the therapy of dual disorder.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Review Medicine, General & Internal

Bipolar Disorder and Comorbid Use of Illicit Substances

Ulrich W. Preuss, Martin Schaefer, Christoph Born, Heinz Grunze

Summary: Substance use disorders are highly prevalent in bipolar disorder and significantly impact clinical outcomes. The reasons behind the higher risk of addictive disorders in individuals with bipolar disorder are not yet clear, but there are common neurobiological and genetic factors. Comprehensive multidisciplinary approaches are needed for the treatment of SUD in bipolar disorder, with limited evidence on the effectiveness of certain medications and neuroprotective agents. More research and clinical trials are necessary for evidence-based best practices.

MEDICINA-LITHUANIA (2021)

暂无数据